tirzepatide and gout Joint Inflammation: What the Evidence Shows SURPASS-CVOT: Tirzepatide Significantly Reduces Major
Description
Zepbound) to be covered if the preferred option is not clinically inappropriate
*Correspondence: Juan Huang, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
However, special care should be taken with children or those with underlying health conditions
Watch the safety data closely
